Mualliflar

  • Мирсаидова У.А.

##semicolon##

эндокринные заболевания, дерматопатии, псориаз, витилиго, метаболический синдром.

##submission.citations##

World Health Organization. Obesity and overweight. Fact Sheet. 2021. Available from: https: //www.who.int/news-room/fact-sheets/detail/ob-esity-and-overweight

Атлас диабета IDF 2025. https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/

Singh S., Young P., Armstrong A. W. An update on psoriasis and metabolic syndrome: A meta‑analysis of observational studies. PLOS ONE. 2017;12(7): e0181039. doi: 10.1371/journal.pone.0 181039

Jing‑Ji Jin, San‑Wu Zeng. Association between psoriasis and metabolic syndrome: a meta‑ analysis from 12 case‑control studies. Int J Clin Exp Med. 2016;9(9):17933‑17939. Received April 26, 2016; Accepted July 30, 2016; Epub September 15, 2016; Published September 30, 2016.

Bu J., Ding R., Zhou L. et al. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front Immunol. 2022;13:880201. doi: 10.338 9/fimmu.2022.880201.

Hu Z., Wang T. Beyond skin white spots: Vitiligo and associated comorbidities. Front Med (Lausanne). 2023;10:1072837. doi: 10.3389/fmed. 2023.1072837.

Kantor J. Quality of life and genital dermatoses. J Am Acad Dermatol. 2025: S0190‑9622 (25) 02549‑6. doi: 10.1016/j.jaad.2025.07.058.

Rodríguez‑Zúñiga M., García‑Perdomo H. Systematic review and meta‑analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017;77(4): 657‑666.e8. doi: 10.1016/j.jaad.2017.04.1133.

Love T., Qureshi A., Karlson E. et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003‑2006. Arch Dermatol. 2011;147(4):41 9‑24. doi: 10.1001/archdermatol.2010.370.

Baldini E., Odorisio T., Sorrenti S. et al. Vitiligo and Autoimmune Thyroid Disorders. Front Endocrinol (Lausanne). 2017; 8: 290. doi: 10.3389/fen-do.2017.00290.

Yuan J., Sun C., Jiang S. et al. The Prevalence of Thyroid Disorders in Patients With Vitiligo: A Systematic Review and Meta‑Analysis. Front Endocrinol (Lausanne). 2019; 9: 803. doi: 10.3389/fendo.2018.0 0803.

Stratakis C. Skin manifestations of Cushing's syndrome. Rev Endocr Metab Disord. 2016; 17(3):283‑286. doi: 10.1007/s11154‑016‑9399‑3.

Pivonello R., Isidori A., De Martino M. et al. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611‑29. doi: 10.1016/S2213‑8587(16)00086‑3.

Schmidt T., Shinkai K. Evidence‑based approach to cutaneous hyperandrogenism in women. J Am Acad Dermatol. 2015;73(4):672‑90. doi: 10.10 16/j.jaad.2015.05.026.

Taieb A., Feryel A. Deciphering the Role of Androgen in the Dermatologic Manifestations of Polycystic Ovary Syndrome Patients: A State‑of‑the‑Art Review. Diagnostics (Basel). 2024;14(22):2578. doi: 10.3390/diagnostics14222578.

Ashraf S., Nabi M., Rasool S. et al. Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review. Egypt J Med Hum Genet. 2019; 20: 10. doi: 10.1186/s43042‑019‑00 31‑4.

Sheth V., Guo Y., Qureshi A. Comorbidities associated with vitiligo: a ten‑year retrospective study. Dermatology. 2013;227(4):311‑315. doi: 10. 1159/000354607.